RS
AMLX icon

R Squared’s Amylyx Pharmaceuticals AMLX Stock Holding History

R Squared’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,736
Closed -$45.1K – 466
2025
Q1 		$45.1K Buy
12,736
+6,366
+100% +$22.7K 0.05% 256
2024
Q4 		$24.1K Buy
+6,370
New +$30K 0.02% 794

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

R Squared's AMLX Position: Q2 2025 in Review

R Squared sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 12,736 shares — an estimated $45.1K sold.

R Squared first reported a position in AMLX in Q4 2024 and held it in 2 quarters. The position peaked at $45.1K in Q1 2025. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • R Squared reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • R Squared sold 12,736 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $45.1K.
  • R Squared first reported a position in Amylyx Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • R Squared's Amylyx Pharmaceuticals position peaked at $45.1K in Q1 2025.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on R Squared's 13F filing for Q2 2025, filed 31 Jul 2025.